Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of subcutaneous efgartigimod PH20 in adults with ocular myasthenia gravis
2024-514133-38-00Phase 3Authorised
- Sponsor
- argenx
- Start
- Mar 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Vyvgart PH20 SC with Placebo PH20 SC (2 arms). Primary endpoint: MGII (PRO) ocular score change from baseline to day 29 in part A. Planned start Mar 2025; status: authorised.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2024-514133-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514133-38-00.